MetLife Investment Management’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.37M | Sell |
25,317
-408
| -2% | -$80.1K | 0.02% | 612 |
|
|
2026
Q1 | $5.04M | Sell |
25,725
-944
| -4% | -$183K | 0.03% | 616 |
|
|
2025
Q4 | $4.63M | Sell |
26,669
-1,067
| -4% | -$194K | 0.02% | 662 |
|
|
2025
Q3 | $5.29M | Sell |
27,736
-704
| -2% | -$125K | 0.03% | 610 |
|
|
2025
Q2 | $5.11M | Sell |
28,440
-388
| -1% | -$67.4K | 0.03% | 570 |
|
|
2025
Q1 | $4.88M | Sell |
28,828
-700
| -2% | -$115K | 0.03% | 624 |
|
|
2024
Q4 | $4.45M | Buy |
29,528
+591
| +2% | +$91.9K | 0.02% | 626 |
|
|
2024
Q3 | $4.49M | Sell |
28,937
-690
| -2% | -$103K | 0.03% | 592 |
|
|
2024
Q2 | $4.06M | Buy |
29,627
+3,620
| +14% | +$496K | 0.02% | 606 |
|
|
2024
Q1 | $3.46M | Sell |
26,007
-1,277
| -5% | -$166K | 0.02% | 702 |
|
|
2023
Q4 | $3.76M | Sell |
27,284
-469
| -2% | -$61.7K | 0.03% | 640 |
|
|
2023
Q3 | $3.38M | Sell |
27,753
-673
| -2% | -$89.7K | 0.03% | 645 |
|
|
2023
Q2 | $4M | Sell |
28,426
-210
| -0.7% | -$28.9K | 0.03% | 582 |
|
|
2023
Q1 | $4.05M | Sell |
28,636
-1,097
| -4% | -$157K | 0.03% | 586 |
|
|
2022
Q4 | $4.65M | Sell |
29,733
-1,223
| -4% | -$176K | 0.04% | 481 |
|
|
2022
Q3 | $3.8M | Sell |
30,956
-651
| -2% | -$85.7K | 0.03% | 555 |
|
|
2022
Q2 | $4.2M | Sell |
31,607
-829
| -3% | -$113K | 0.03% | 530 |
|
|
2022
Q1 | $4.44M | Buy |
32,436
+5,333
| +20% | +$743K | 0.03% | 613 |
|
|
2021
Q4 | $4.69M | Sell |
27,103
-492
| -2% | -$74.9K | 0.04% | 429 |
|
|
2021
Q3 | $4.01M | Sell |
27,595
-2,692
| -9% | -$394K | 0.04% | 479 |
|
|
2021
Q2 | $4M | Sell |
30,287
-1,514
| -5% | -$198K | 0.04% | 508 |
|
|
2021
Q1 | $4.08M | Sell |
31,801
-927
| -3% | -$114K | 0.04% | 496 |
|
|
2020
Q4 | $3.9M | Sell |
32,728
-1,323
| -4% | -$161K | 0.04% | 475 |
|
|
2020
Q3 | $3.9M | Sell |
34,051
-924
| -3% | -$109K | 0.04% | 404 |
|
|
2020
Q2 | $3.99M | Buy |
34,975
+256
| +0.7% | +$27.2K | 0.05% | 390 |
|
|
2020
Q1 | $2.79M | Sell |
34,719
-1,063
| -3% | -$110K | 0.04% | 468 |
|
|
2019
Q4 | $3.82M | Sell |
35,782
-866
| -2% | -$90.3K | 0.04% | 493 |
|
|
2019
Q3 | $3.92M | Sell |
36,648
-391
| -1% | -$40.1K | 0.04% | 451 |
|
|
2019
Q2 | $3.77M | Sell |
37,039
-1,128
| -3% | -$108K | 0.04% | 491 |
|
|
2019
Q1 | $3.43M | Sell |
38,167
-746
| -2% | -$64.6K | 0.04% | 539 |
|
|
2018
Q4 | $3.24M | Sell |
38,913
-842
| -2% | -$78.9K | 0.04% | 500 |
|
|
2018
Q3 | $4.29M | Sell |
39,755
-226
| -0.6% | -$24.8K | 0.04% | 434 |
|
|
2018
Q2 | $4.4M | Sell |
39,981
-838
| -2% | -$87.3K | 0.05% | 366 |
|
|
2018
Q1 | $4.09M | Sell |
40,819
-1,353
| -3% | -$139K | 0.05% | 421 |
|
|
2017
Q4 | $4.15M | Buy |
+42,172
| New | +$4M | 0.05% | 438 |
|
Other funds holding DGX
EIG
MetLife Investment Management's DGX Position: Q2 2026 in Review
MetLife Investment Management reduced its Quest Diagnostics (DGX) stake by 1.6% in Q2 2026, selling an estimated $80.1K and leaving 25,317 shares worth $5.37M. The position accounts for 0.02% of the portfolio, ranked #612.
MetLife Investment Management first reported a position in DGX in Q4 2017 and has held it in 35 quarters since. 1,100 funds tracked by Wall St. Rank hold DGX as of Q2 2026.
- MetLife Investment Management held 25,317 shares of Quest Diagnostics worth $5.37M as of Q2 2026.
- MetLife Investment Management sold 408 Quest Diagnostics shares in Q2 2026, an estimated $80.1K.
- Quest Diagnostics made up 0.02% of MetLife Investment Management's portfolio in Q2 2026, its #612 holding.
- MetLife Investment Management first reported a position in Quest Diagnostics in Q4 2017 and has held it in 35 quarters since.
- 1,100 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.
Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.